BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8841971)

  • 21. Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings.
    Hartmann AP; Almeida SM; Livramento JA; Nitrini R; Takahashi D; Caramelli P
    Arq Neuropsiquiatr; 2004 Sep; 62(3B):751-5. PubMed ID: 15476062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease.
    Santos JRF; Bauer C; Schuchhardt J; Wedekind D; Waniek K; Lachmann I; Wiltfang J; Vogelgsang J
    J Neural Transm (Vienna); 2019 Mar; 126(3):339-348. PubMed ID: 30767082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease.
    Tapiola T; Lehtovirta M; Ramberg J; Helisalmi S; Linnaranta K; Riekkinen P; Soininen H
    Neurology; 1998 Jan; 50(1):169-74. PubMed ID: 9443475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis.
    Struyfs H; Van Broeck B; Timmers M; Fransen E; Sleegers K; Van Broeckhoven C; De Deyn PP; Streffer JR; Mercken M; Engelborghs S
    J Alzheimers Dis; 2015; 45(3):813-22. PubMed ID: 25633670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
    de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
    J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease.
    Golombowski S; Müller-Spahn F; Romig H; Mendla K; Hock C
    Neurosci Lett; 1997 Apr; 225(3):213-5. PubMed ID: 9147408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
    Galasko D
    J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer's Disease.
    Schmidt C; Gerlach N; Schmitz M; Thom T; Kramer K; Friede T; Zerr I
    J Alzheimers Dis; 2015; 48(1):189-96. PubMed ID: 26401939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.
    Iqbal K; Flory M; Khatoon S; Soininen H; Pirttila T; Lehtovirta M; Alafuzoff I; Blennow K; Andreasen N; Vanmechelen E; Grundke-Iqbal I
    Ann Neurol; 2005 Nov; 58(5):748-57. PubMed ID: 16247771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.
    Green AJ; Harvey RJ; Thompson EJ; Rossor MN
    Neurosci Lett; 1999 Jan; 259(2):133-5. PubMed ID: 10025576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.